RemeGen (09995) and Vor Bio Sign Amendment to the License Agreement

Zhitong Finance APP News, RemeGen (09995) announced that, in order to further enrich the product portfolios of both parties in the global autoimmune field under the license agreement and accelerate the international development of the Company's innovative pipeline, on November 12, 2026, the Company and Vor Bio signed an amendment agreement to the license agreement (the Amendment Agreement), bringing RC298 (the Licensed Product), for which the Company owns independent intellectual property rights, into the scope of cooperation. Vor Bio will obtain exclusive rights to develop and commercialize RC298 in the global territory (excluding Greater China (i.e., Mainland China, Hong Kong, Macau, and Taiwan)) (the Licensed Territory).